ASRT Stock Overview
Assertio Holdings, Inc., a commercial pharmaceutical company, provides various products to patients in the United States.
Snowflake Score | |
---|---|
Valuation | 5/6 |
Future Growth | 3/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Assertio Holdings, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$1.22 |
52 Week High | US$8.01 |
52 Week Low | US$0.73 |
Beta | 1.0 |
1 Month Change | 28.72% |
3 Month Change | 52.98% |
1 Year Change | -80.51% |
3 Year Change | -40.43% |
5 Year Change | -92.87% |
Change since IPO | -92.38% |
Recent News & Updates
Does Assertio Holdings (NASDAQ:ASRT) Have A Healthy Balance Sheet?
Apr 18Improved Revenues Required Before Assertio Holdings, Inc. (NASDAQ:ASRT) Stock's 26% Jump Looks Justified
Mar 13Recent updates
Does Assertio Holdings (NASDAQ:ASRT) Have A Healthy Balance Sheet?
Apr 18Improved Revenues Required Before Assertio Holdings, Inc. (NASDAQ:ASRT) Stock's 26% Jump Looks Justified
Mar 13We Think Assertio Holdings (NASDAQ:ASRT) Can Stay On Top Of Its Debt
Apr 26Is There An Opportunity With Assertio Holdings, Inc.'s (NASDAQ:ASRT) 23% Undervaluation?
Mar 02Assertio Holdings Looks Good To Rebound After Recent Price Plunge
Sep 07Assertio Holdings: Substantial Upside
Aug 21Assertio Therapeutics Q2 2022 Earnings Preview
Aug 05Assertio Holdings: Management Still Swimming Against The Tide
Jun 10Assertio's Phenomenal Turnaround
May 19Assertio Holdings: Recent Breakout To Lead To Sustained Gains
Apr 07Assertio's Digital Strategy Looks To Be Paying Off
Jan 21Assertio shares rise on Q1 revenue strength, provides FY forecast
May 07Assertio announces restructuring plan and leadership change
Dec 15Assertio Therapeutics EPS misses by $0.05, beats on revenue
Nov 06Shareholder Returns
ASRT | US Pharmaceuticals | US Market | |
---|---|---|---|
7D | 43.9% | 2.3% | 1.6% |
1Y | -80.5% | 10.8% | 25.1% |
Return vs Industry: ASRT underperformed the US Pharmaceuticals industry which returned 9.4% over the past year.
Return vs Market: ASRT underperformed the US Market which returned 23.9% over the past year.
Price Volatility
ASRT volatility | |
---|---|
ASRT Average Weekly Movement | 10.7% |
Pharmaceuticals Industry Average Movement | 10.2% |
Market Average Movement | 6.1% |
10% most volatile stocks in US Market | 16.7% |
10% least volatile stocks in US Market | 3.0% |
Stable Share Price: ASRT's share price has been volatile over the past 3 months.
Volatility Over Time: ASRT's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2020 | 53 | Heather Mason | www.assertiotx.com |
Assertio Holdings, Inc., a commercial pharmaceutical company, provides various products to patients in the United States. Its pharmaceutical products include INDOCIN, an oral and suppository solution for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. It also provides Sympazan, a benzodiazepine for the adjunctive treatment of seizures related with lennox-gastaut syndrome in patients aged two years of age or older; CAMBIA, a non steroidal anti inflammatory drug (NSAID) for the treatment of migraine pain, nausea, photophobia, and phonophobia; Zipsor, a NSAID for relief of mild to moderate pain in adults; SPRIX, a NSAID for the short term management of moderate to moderately severe pain that requires analgesia at the opioid level; Otrexup, a single-dose auto-injector containing a prescription medicine and methotrexate that is used to treat patients with severe, active rheumatoid arthritis, and active polyarticular juvenile idiopathic arthritis, as well as treat adult with severe, recalcitrant, and disabling psoriasis; and ROLVEDON, a long-acting granulocyte colony-stimulating factor that is indicated to decrease the incidence of infection caused by febrile neutropenia.
Assertio Holdings, Inc. Fundamentals Summary
ASRT fundamental statistics | |
---|---|
Market cap | US$116.05m |
Earnings (TTM) | -US$331.94m |
Revenue (TTM) | US$152.07m |
0.8x
P/S Ratio-0.3x
P/E RatioIs ASRT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
ASRT income statement (TTM) | |
---|---|
Revenue | US$152.07m |
Cost of Revenue | US$27.02m |
Gross Profit | US$125.05m |
Other Expenses | US$456.99m |
Earnings | -US$331.94m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -3.49 |
Gross Margin | 82.23% |
Net Profit Margin | -218.28% |
Debt/Equity Ratio | 27.9% |
How did ASRT perform over the long term?
See historical performance and comparison